The next generation of therapies for chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for chronic myeloid leukemia (CML).
• Imatinib resistance, often due to BCR-ABL1 kinase domain mutations, limits treatment efficacy.
• Minimal residual disease (MRD) persists in many patients, highlighting treatment limitations.

Purpose of the Study:

• To review current research on managing imatinib-resistant mutations in CML.
• To discuss strategies for overcoming the T315I mutation, a key resistance mechanism.
• To explore methods for eradicating minimal residual disease in CML patients.

Main Methods:

• Review of current scientific literature on CML treatment resistance and MRD.
• Analysis of emerging therapeutic strategies targeting BCR-ABL1 mutations.
• Discussion of ongoing research in CML management.

Main Results:

• Most BCR-ABL1 mutations conferring imatinib resistance can be overcome by second-generation TKIs.
• The T315I mutation remains a significant challenge, resistant to current TKI therapies.
• Eradication of minimal residual disease is crucial for long-term CML remission.

Conclusions:

• Further research is needed to develop effective therapies against the T315I mutation.
• Strategies to eliminate minimal residual disease are essential for achieving a functional cure in CML.
• Advancements in TKI therapy and novel approaches are critical for improving CML patient outcomes.